Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells

BACKGROUND: Triple-negative breast cancer (TNBC) has aggressive progression with poor prognosis and ineffective treatments. Selumetinib is an allosteric, ATP-noncompetitive inhibitor of MEK1/2, which has benn known as effective antineoplastic drugs for several malignant tumors. We hypothesized that...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Zhou, Yan, Lin, Shuchen, Tseng, Kuo-Fu, Han, Kun, Wang, Yaling, Gan, Zhi-hua, Min, Da-liu, Hu, Hai-yan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5073736/
https://ncbi.nlm.nih.gov/pubmed/27769200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2773-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia